Novartis Cosentyx wins NICE backing for non-radiographic axial spondyloarthritis pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
EXTON, Pa., Feb. 17, 2021 /PRNewswire/ Approved just two weeks apart in June of last year for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA), in-class competitors, Novartis Cosentyx and Eli Lilly s Taltz, have since experienced rapid uptake. According to feedback from 97 US rheumatologists in the latest report included in Spherix s
RealTime Dynamix
™ service, the official entrance of the IL-17 inhibitors is causing a shift in the market where UCB s Cimzia previously held the position as the only biologic with commercial availability.
The report, which highlights the differences in referral, diagnostic, and management patterns of ankylosing spondylitis (AS) and nr-axSpA patients, found that the incidence of biologic/JAK treatment (including off-label use) remains higher in AS than it does in nr-axSpA. However, biologic treatment in moderate and severe forms of nr-axSpA has seen growth over the last few years, owin
Share this article
Share this article
EXTON, Pa., Feb. 10, 2021 /PRNewswire/ Despite the potential for setbacks brought forth by the COVID-19 pandemic, Amgen recently reported strong year-over-year growth for their newly acquired psoriasis (PSO) and psoriatic arthritis (PsA) agent, Otezla.
1 In late 2019, the brand was sold to Amgen in order to clear the path for Bristol-Myers Squibb s acquisition of Celgene, considering future regulatory conflicts with BMS pipeline psoriasis drug, deucravacitinib, an oral TYK2 inhibitor anticipated to be in direct competition with Otezla.
Amgen s purchase of Otezla strengthens the company s long-standing immunology portfolio, including TNF inhibitor, Enbrel, which has been approved in RA for over two decades and also holds a dual PSO/PsA indication. However, according to ongoing feedback collected from US dermatologists and rheumatologists included in Spherix s
Spherix Global Insights Introduces New Service Focusing on Recent Launches in Expanding Immunology, Nephrology, and Neurology Markets
The Launch Dynamix™ service includes current tracking of Cosentyx (Novartis) and Taltz (Eli Lilly) in non-radiographic axial spondyloarthritis, Kesimpta (Novartis) in multiple sclerosis, Stelara (Janssen) in ulcerative colitis, Tremfya (Janssen) in psoriatic arthritis, and Benlysta (GSK) and Lupkynis (Aurinia) in lupus nephritis
News provided by
Share this article
Share this article
EXTON, Pa., Jan. 29, 2021 /PRNewswire/ Spherix Global Insights, a leading market intelligence firm specializing in select dermatology, gastroenterology, nephrology, neurology, and rheumatology markets, announces the inaugural publications of their newest service offering,